• Home
  • Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.

Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial.

Author List
Monga V, Okuno S, Van Tine B, Pollack SM, Weiss M, Hirbe A, Viveiros P, Schulte B, Attia S, Siontis B, Milhem MM, Charlson JA, Robinson S, Okunowo O, Frankel P, Woo D, Yoon J, Agulnik M
Publication
The Lancet. Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/732142230
Publication Year
2026
PubMed ID
41554272
Publication Title
Monga V, Okuno S, Van Tine B, Pollack SM, Weiss M, Hirbe A, Viveiros P, Schulte B, Attia S, Siontis B, Milhem MM, Charlson JA, Robinson S, Okunowo O, Frankel P, Woo D, Yoon J, Agulnik M. Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial. Lancet Oncol. 2026 Jan 16.
Publication Medline TA
Lancet Oncol
Date
2026-01-16